lysine conjugate 3

Lysine conjugate 3 is an experimental, heterogeneous antibody-drug conjugate (ADC) developed as a comparative control in preclinical research investigating the impact of ADC homogeneity on therapeutic efficacy in glioblastoma multiforme (GBM). It consists of a mutant anti-EGFR monoclonal antibody (cetuximab with N88A/N297A mutations) randomly conjugated to the cytotoxic payload monomethyl auristatin F (MMAF) via a non-cleavable N-hydroxysuccinimide (NHS) ester linker. Designed to mimic the heterogeneous conjugation modality of clinical-stage ADCs such as AMG-595, lysine conjugate 3 serves as a research tool to study blood-brain barrier (BBB) penetration. Preclinical studies published in 2022 demonstrated that this heterogeneous conjugate exhibits significantly poorer brain tumor delivery and reduced survival benefits compared to site-specific, homogeneous ADCs. The research specifically identified that the highly drug-loaded species (high drug-to-antibody ratio) within the heterogeneous mixture of lysine conjugate 3 are particularly ineffective at crossing the BBB, thereby limiting the overall targeting and efficacy of the drug in intracranial tumor models.